

REMARKS

After the amendments made herein, Claims 1-29 and 36-42 are pending. The Applicants herein amend elected Claims 18-23, 25, 41, and 42 to clarify the claimed subject matter and to correct obvious typographical errors. Therefore, none of these claim amendments introduces any new matter into this application.

ELECTION/RESTRCTION


Claims 1-29 and 36-42 are pending in this application and are subject to a restriction and/or election requirement.

Upon review of the Detailed Action provided by the Examiner, the Applicants elect Group III, Claims 13-28, 41, and 42, without traverse. For the species election, the Applicants elect:

- (1) cancer as the disease;
- (2) SEQ ID NO:1 as the species of CPG adjuvant;
- (3) the MAGE family as the species of tumor-associated antigen; and
- (4) 3D-MPL as the species of adjuvant.

Should the restriction become final, the Applicants reserve the right to prosecute, in one or more patent applications, the claims to non-elected inventions, the claims as originally filed, and any other claims supported by the specification. If it would advance the prosecution of the instant application, the Examiner is invited to confer with the Applicants' undersigned patent attorney by telephone.

Respectfully submitted,



Elizabeth J. Hecht
Attorney for Applicants
Registration No. 41,824

GlaxoSmithKline Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5009
Facsimile (610) 270-5090

N:\EJH\APPLNSV cases\VB60529\RestrictReq 07Feb08\PrelimAmendRestrictReq.doc